M. C. Martinez-Campanario

M. C. Martinez-Campanario

Auto-generated profile, based on publicly available information

M. C. Martinez-Campanario

Group of Gene Regulation in Stem Cells, Cell Plasticity, Differentiation, and Cancer, IDIBAPS, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MCMarlies Cortés
Marlies Cortés
ABAgnese Brischetto
Agnese Brischetto
MMM. C. Martinez-Campanario
M. C. Martinez-Campanario
CNChiara Ninfali
Chiara Ninfali
VDVerónica Domínguez
Verónica Domínguez
APAntonio Postigo
Antonio Postigo
Acute inflammation can either resolve through immunosuppression or persist, leading to chronic inflammation. These transitions are driven by distinct molecular and metabolic reprogramming of immune cells. The anti-diabetic drug Metformin inhibits acute and chronic inflammation through mechanisms still not fully understood. Here, we report that the anti-inflammatory and reactive-oxygen-species-inhibiting effects of Metformin depend on the expression of the plasticity factor ZEB1 in macrophages. Using mice lacking Zeb1 in their myeloid cells and human patient samples, we show that ZEB1 plays a dual role, being essential in both initiating and resolving inflammation by inducing macrophages to transition into an immunosuppressed state. ZEB1 mediates these diverging effects in inflammation and immunosuppression by modulating mitochondrial content through activation of autophagy and inhibition of mitochondrial protein translation. During the transition from inflammation to immunosuppression, Metformin mimics the metabolic reprogramming of myeloid cells induced by ZEB1. Mechanistically, in immunosuppression, ZEB1 inhibits amino acid uptake, leading to downregulation of mTORC1 signalling and a decrease in mitochondrial translation in macrophages. These results identify ZEB1 as a driver of myeloid cell metabolic plasticity, suggesting that targeting its expression and function could serve as a strategy to modulate dysregulated inflammation and immunosuppression.

14 December 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMM. C. Martinez-Campanario
M. C. Martinez-Campanario
MCMarlies Cortés
Marlies Cortés
AMAlazne Moreno-Lanceta
Alazne Moreno-Lanceta
LHLu Han
Lu Han
CNChiara Ninfali
Chiara Ninfali
APAntonio Postigo
Antonio Postigo
Accumulation of lipid-laden macrophages within the arterial neointima is a critical step in atherosclerotic plaque formation. Here, we show that reduced levels of the cellular plasticity factor ZEB1 in macrophages increase atherosclerotic plaque formation and the chance of cardiovascular events. Compared to control counterparts (Zeb1WT/ApoeKO), male mice with Zeb1 ablation in their myeloid cells (Zeb1∆M/ApoeKO) have larger atherosclerotic plaques and higher lipid accumulation in their macrophages due to delayed lipid traffic and deficient cholesterol efflux. Zeb1∆M/ApoeKO mice display more pronounced systemic metabolic alterations than Zeb1WT/ApoeKO mice, with higher serum levels of low-density lipoproteins and inflammatory cytokines and larger ectopic fat deposits. Higher lipid accumulation in Zeb1∆M macrophages is reverted by the exogenous expression of Zeb1 through macrophage-targeted nanoparticles. In vivo administration of these nanoparticles reduces atherosclerotic plaque formation in Zeb1∆M/ApoeKO mice. Finally, low ZEB1 expression in human endarterectomies is associated with plaque rupture and cardiovascular events. These results set ZEB1 in macrophages as a potential target in the treatment of atherosclerosis.

25 September 2025 in Seminars in Cancer Biology
Verified
Journal Article
Open access
MMMC Martinez-Campanario
MC Martinez-Campanario
MCMarlies Cortés
Marlies Cortés
LHLu Han
Lu Han
ABAgnese Brischetto
Agnese Brischetto
PRPaloma Rivero-Soriano
Paloma Rivero-Soriano
APAntonio Postigo
Antonio Postigo
This review explores the dual roles of lipid-laden macrophages (LL-Macs) in inflammation, atherosclerosis and cancer, emphasizing both their shared and divergent functions across physiological and pathological conditions. Lipid metabolism regulates the polarization of macrophages in homeostasis and inflammation. In atherosclerosis, LL-Macs contribute to plaque formation and inflammation, while in cancer, LL-Macs play crucial roles in immune suppression and tumor progression. The article outlines the molecular mechanisms driving macrophage lipid accumulation in each of these scenarios and how the process is influenced by the distinct local microenvironments in inflammation, atherosclerosis and cancer. Single-cell RNA sequencing (scRNA-seq) studies have identified both common and unique gene signatures between LL-Macs in atherosclerosis and cancer, reflecting the varying microenvironmental cues that shape macrophage function and disease outcomes. Finally, we examine lipid-modulating strategies in atherosclerosis, assess their potential in cancer treatment, and highlight research gaps for developing new LL-Macs targeted therapies in cancer.

10 November 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
CNChiara Ninfali
Chiara Ninfali
MCMarlies Cortés
Marlies Cortés
MMM. C. Martínez-Campanario
M. C. Martínez-Campanario
VDVerónica Domínguez
Verónica Domínguez
LHLu Han
Lu Han
APAntonio Postigo
Antonio Postigo
Reactive oxygen species (ROS) serve important homeostatic functions but must be constantly neutralized by an adaptive antioxidant response to prevent supraphysiological levels of ROS from causing oxidative damage to cellular components. Here, we report that the cellular plasticity transcription factors ZEB1 and ZEB2 modulate in opposing directions the adaptive antioxidant response to fasting in skeletal muscle. Using transgenic mice in which Zeb1 or Zeb2 were specifically deleted in skeletal myofibers, we show that in fasted mice, the deletion of Zeb1 , but not Zeb2 , increased ROS production and that the adaptive antioxidant response to fasting essentially requires ZEB1 and is inhibited by ZEB2. ZEB1 expression increased in fasted muscles and protected them from atrophy; conversely, ZEB2 expression in muscles decreased during fasting and exacerbated muscle atrophy. In fasted muscles, ZEB1 reduces mitochondrial damage and increases mitochondrial respiratory activity; meanwhile, ZEB2 did the opposite. Treatment of fasting mice with Zeb1 -deficient myofibers with the antioxidant triterpenoid 1[2-cyano-3,12-dioxool-eana-1,9(11)-dien-28-oyl] trifluoro-ethylamide (CDDO-TFEA) completely reversed their altered phenotype to that observed in fasted control mice. These results set ZEB factors as potential therapeutic targets to modulate the adaptive antioxidant response in physiopathological conditions and diseases caused by redox imbalance.